Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The efficacy of irreversible and reversible monoamine oxidase inhibitors (MAOIs) in the treatment of social phobia (SP) is well established. Recently, selective serotonin reuptake inhibitors (SSRIs) have been used more frequently. In the present study, the efficacy and side‐effect profile of citalopram, an SSRI, and moclobemide, the only MAOI used in Turkey, were compared. The 71 patients diagnosed with SP according to DSM‐III‐R were randomly assigned to two subgroups; citalopram (n = 36) or moclobemide (n = 35). The study was an 8‐week, randomized, open‐label, rater‐blinded, parallel‐group trial. All patients were assessed by Hamilton anxiety rating (HAM‐A), Liebowitz social anxiety (LSAS), clinical global impression‐severity of illness (CGI‐SI) and clinical global impression‐improvement (CGI‐I) scales. There was a similar percentage of responders (citalopram 75%, n = 27 and moclobemide 74.3%, n = 26), with a >50% or greater reduction in LSAS total score and ratings of ‘very much’ or ‘much improved’ on the CGI‐I. None of the patients withdrew from the study. The results of the present study suggest that citalopram has shown promising results in patients with SP. Copyright © 2002 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 2×
“Both irreversible monoamine oxidase inhibitors (MAOIs) such as phenelzine (Liebowitz et al., 1992) and reversible MAOIs such as moclobemide and brofaromine (Versiani et al., 1992; Fahlen et al., 1995) have been shown to be effective in SP.”
BackgroundSocial Phobia Subtypes in the National Comorbidity Survey
Kessler, R. C., Stein, M. B., & Berglund, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.613 · Cited by 398 · cited 1×
“In a national field study, the lifetime prevalence of SP has been reported to be 13.3% (Kessler et al., 1998).”
BackgroundInfluentialSocial phobia in general health care: an unrecognised undertreated disabling disorder
Weiller, E., Bisserbe, J. C., Boyer, P., Lepine, J. P., & Lecrubier, Y. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.2.169 · Cited by 219
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Caldiroli, A., Capuzzi, E., Tagliabue, I., Ledda, L., Clerici, M., & Buoli, M. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2159373 · Cited by 2
Metadata
- Authors
- Atmaca, M., Kuloglu, M., Tezcan, E., & Unal, A.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2002-09-17
- Volume
- 17
- Issue
- 8
- Pages
- 401-405
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2018996292
- Cited by
- 18
- References
- 3
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. https://app.cochat.ai/papers/10.1002/hup.436
- The paper
- Atmaca, M., Kuloglu, M., Tezcan, E., & Unal, A. (2002). Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.